bioAffinity
  • Home
  • Publications
  • News
  • About
  • Contact
  • Investor Relations
Select Page
  • Home
  • Publications
  • News
  • About
  • Contact
  • Investor Relations

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Overview
    • Press Releases
    • IR Calendar
    • Email Alerts
  • Company Info
    • Overview
    • Management Team
    • Presentations
    • Contacts
    • FAQ
  • Financial Info
    • Overview
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Data
    • Quote
    • Charts
    • Historical Data
    • Analyst Coverage
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
    • Board Diversity
  • News & Events

  • Overview
  • Press Releases
  • IR Calendar
  • Email Alerts
May 08, 2025 9:00am EDT

Independent White Paper Highlights Real-World Impact of bioAffinity Technologies’ CyPath® Lung in Diagnosing Early-Stage Lung Cancer

May 07, 2025 1:00pm EDT

bioAffinity Technologies Announces Closing of $3.25 Million Offering

May 06, 2025 9:25am EDT

bioAffinity Technologies Announces Pricing of $3.25 Million Offering

Apr 17, 2025 9:15am EDT

bioAffinity Technologies Increases Efficiency of CyPath® Lung Test by Boosting Data Acquisition Throughput by 50% and Reducing Unit Cost

Mar 31, 2025 9:28am EDT

bioAffinity Technologies Reports Record $9.4 Million Revenue for 2024

Mar 26, 2025 9:00am EDT

Case Study: bioAffinity Technologies’ CyPath® Lung Detects Second Primary Lung Cancer in Patient With History of Lung Cancer

Mar 19, 2025 9:00am EDT

Case Study: bioAffinity Technologies’ Positive CyPath® Lung Result Leads to Detecting Breast Cancer Recurrence

Mar 13, 2025 9:00am EDT

Physicians’ Case Studies Offer Insight into Use and Benefit of CyPath® Lung in Avoiding Unnecessary Invasive Procedures and Detecting Lung Cancer

Mar 06, 2025 8:00am EST

bioAffinity Technologies Announces Targeted Actions to Cut $4 Million in Costs and Drive CyPath® Lung Sales Growth

Feb 26, 2025 11:30am EST

bioAffinity Technologies Announces Closing of Warrant Inducement Transaction for Aggregate Gross Proceeds of $1.4 Million

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • …13
  • arrow_forward
rss_feed News RSS
  • Email Alerts
  • Contacts
  • RSS News Feed


Phone

(210) 698-5334



Email

info@bioaffinitytech.com



LinkedIn

…/bioaffinitytechnologies



Twitter

@bioAffinity

Subscribe for News from bioAffinity Technologies

Subscribe
Copyright © 2025 bioAffinity Technologies, Inc.